Trial reportInvestigational new drugs2007
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
Trial report in Investigational new drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?Frontiers in oncology · 2021Pooled it
- Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Investigational new drugs · 2013Trial
- Phase II study of sunitinib malate in head and neck squamous cell carcinoma.Investigational new drugs · 2010Trial
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.The Lancet. Oncology · 2009Trial
- Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.Journal of cancer research and clinical oncology · 2023Article
- Small molecule inhibitors targeting the cancers.MedComm · 2022Review
- Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.Frontiers in oncology · 2021Review
- Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.European radiology · 2018Article
- The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells.Oncotarget · 2017Article
- Targeting angiogenesis for treatment of human cancer.Indian journal of pharmaceutical sciences · 2013Article
- The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Cold Spring Harbor perspectives in medicine · 2012Review
- SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.PloS one · 2012Article
- Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma.ISRN surgery · 2012Article
- Review
- Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.PloS one · 2011Article
- From antiangiogenesis to hypoxia: current research and future directions.Cancer management and research · 2010Article
- Targeting non-malignant disorders with tyrosine kinase inhibitors.Nature reviews. Drug discovery · 2010Review
- Vascular endothelial growth factor receptor-2 in breast cancer.Biochimica et biophysica acta · 2010Review
- Review
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.British journal of cancer · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. PATIENTS AND
methodsThis was an open label, single arm, Phase 2 study for patients who had received no more than 2 cytotoxic regimens. Thirty-five patients received intravenous SU5416 (145 mg/m(2)) twice per week by intravenous catheter. Radiologic imaging for response assessment was planned at the conclusion of each 8 week cycle. Serum VEGF levels and power Doppler ultrasound tumor imaging were explored as potential surrogate markers for SU5416 activity.
resultsThirty-two patients had received prior radiotherapy, including 18 patients who received prior concurrent chemoradiotherapy. Twelve patients had received prior chemotherapy in the recurrent disease setting. Thirty-one patients were evaluable for response. There was one partial response and one minor response. The median number of 8-week cycles received was 1 (range 1-4). Median overall survival was 6.25 months. The most common > or = grade 3 toxicity was headache (31%). There was one fatal carotid artery hemorrhage. Fatigue, nausea, and vomiting were common grade 1-2 adverse events. Power Doppler ultrasound demonstrated decreased tumor vascularity in 5 of 7 patients.
conclusionsTreatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare. Studies evaluating more potent anti-angiogenic agents in this disease are of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.